Managing High‑Severity Exposure in a Changing
Claims Landscape
High‑cost cell and gene therapies are reshaping the distribution of health insurance claims. For organizations operating in stop loss, captive, and alternative risk environments, the challenge is to design and implement pricing, management, and risk strategies that keep pace with the exposure these therapies introduce.
As these treatments move from pipeline to practice, traditional actuarial models grounded primarily in historical claim experience may be inadequate to quantify losses that are low‑frequency, high‑severity, and highly concentrated.
Actuarial Clarity for a Changing Catastrophic Claim Environment
Emerging therapies are reshaping how catastrophic risk is understood across health insurance programs. We help clients assess where this exposure may surface, how it could affect current pricing and risk management assumptions, and what changes to these assumptions may be required.
Exposure Assessment
Understanding how cell and gene therapy risk may emerge within a program’s retained risk is the starting point for effective management. WSP helps organizations assess exposure across stop loss, captive, and pooled structures to clarify how emerging therapies interact with existing pricing, retention, and risk transfer arrangements—and where residual risk may remain.
Pricing and Structural Implications
Cell and gene therapies challenge traditional pricing and structural assumptions by introducing low‑frequency, high‑severity claims that are not present in claims history but can materially impact results. WSP evaluates how these exposures influence pricing adequacy, attachment points, and retained risk, helping clients determine whether existing structures remain appropriate in this evolving environment.
Strategic Response and Sustainability
The long‑term impact to insurance programs of emerging therapies depends on how early and intentionally risk is addressed. WSP supports strategic responses that strengthen sustainability by aligning pricing, benefit structure, and risk‑sharing decisions with the evolving risk environment, helping organizations adapt proactively rather than reactively once experience has emerged.
Planning for High-Severity Claims Before They Overwhelm Experience
Cell and gene therapies represent important medical progress, but they also introduce a significantly different order of financial exposure into health insurance. For organizations operating in stop loss and captive environments, proactive actuarial insight helps clarify how this risk may affect pricing, structure, and long-term sustainability.
How We Help Clients Respond to Emerging Therapy Risk
Understanding the Exposure
We begin by reviewing the organization’s current exposure to high-cost therapy risk through its pricing, retention, product, and risk management environment.
Assessing Severity Implications
We help clarify how emerging therapies may affect catastrophic claim exposure, financial modeling, and the pricing and risk management assumptions currently supporting the business.
Evaluating Structural Impact
We examine what emerging therapy claim risk means for stop loss strategy, captive resilience, and broader questions of sustainability where such claims can be concentrated.
Supporting the Strategic Response
We help clients respond proactively to the changing risk environment, with experienced actuarial insight around pricing, retention, and program structure.